In a move that is likely to surprise many, Reliance has disclosed its biotechnology plans for the future. In true Reliance style, the plans are truly global and big. However, what has come as a surprise is that within 8 months of incorporating Reliance Life Sciences Pvt. Ltd (RLS), the company has been listed by the National Institutes of Health (USA) as one of the ten companies and research institutions working in the area of embryonic stem cells and eligible for federal funds under the new US Presidential guidelines!
As per the companyís press release the cell biology research center of the company located in Mumbai is one of its kind in Asia. The company plans to create one of the largest cord blood repositories in the world, as part of the cell biology centre.
The cell biology centre currently has team strength of 51 members. The cell biology centre of the company is focusing on research and development in stem cells and tissue engineering. The centre aims to deliver novel, affordable cell-based therapies and engineer tissues to address the needs in the Indian and global healthcare markets.
To start with RLS plans to develop novel cures for diseases such as diabetes and Parkinsonís by harnessing the property of immortality of stem cells. The company further plans to offer services in expansion and storage of stem cells, cultured skin, a comprehensive genetic center, blah blah. The list is long.
It seems that Reliance is in no mood to miss the biotech bus.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407